Blood Biomarker Predicts Dementia Risk Years Before Symptoms in Women

A decades-long study of postmenopausal women offers a promising step forward in the early detection of dementia risk. Researchers have found that measuring levels of a blood biomarker, phosphorylated tau 217 (p-tau217), can help identify individuals who may be at higher risk of cognitive decline years before symptoms appear. This minimally invasive test could potentially revolutionize how we approach Alzheimer’s disease and related dementias, offering a window for earlier intervention and potentially slowing disease progression.

Understanding the Biomarker and the Study

Plasma biomarkers, substances measured in blood, are gaining traction as a way to detect early signs of Alzheimer’s disease pathology. P-tau217, in particular, has shown greater accuracy in identifying Alzheimer’s compared to other biomarkers, performing similarly to measurements taken from cerebrospinal fluid (CSF) – a more invasive procedure. The recent study, published in JAMA Network Open, builds on this research by examining the biomarker’s predictive power over decades of follow-up in a large cohort of women.

The study focused on participants from the Women’s Health Initiative Memory Study (WHIMS), a long-running research project that began in 1996. Researchers analyzed blood samples collected at the start of the study from 2,766 postmenopausal women aged 65 to 79. These women were followed for an average of 14.1 years, during which time researchers tracked the development of mild cognitive impairment (MCI) and probable dementia. MCI represents a stage of cognitive decline that is noticeable but doesn’t yet interfere significantly with daily life, while dementia involves a more substantial loss of cognitive function.

Participants in WHIMS were originally enrolled in randomized controlled trials examining the effects of hormone therapy (HT) on cognitive outcomes. Some were assigned to receive estrogen plus progestin, others estrogen alone, and a control group received a placebo. This aspect of the study allowed researchers to investigate whether HT exposure influenced the relationship between p-tau217 levels and cognitive decline.

Key Findings: p-tau217 and Dementia Risk

The study revealed a clear association between higher levels of p-tau217 in the blood and an increased risk of developing either MCI or dementia. The strongest link was observed with dementia; higher p-tau217 levels were significantly associated with a greater likelihood of being diagnosed with probable dementia during the follow-up period. The association with MCI was weaker, suggesting the biomarker may be more strongly predictive of later-stage disease.

Interestingly, the researchers found that the association between p-tau217 and dementia appeared to be influenced by hormone therapy. Women who were assigned to receive estrogen plus progestin showed a larger association between p-tau217 levels and dementia risk compared to those who received a placebo. This suggests that HT, specifically the combination of estrogen and progestin, may interact with the underlying biological processes related to tau accumulation and cognitive decline. However, the interaction wasn’t statistically significant, meaning further research is needed to confirm this finding.

Race, Genetics, and Age: Nuances in the Findings

The study similarly highlighted important differences based on race, genetics, and age. The association between p-tau217 and cognitive decline was more pronounced in White participants compared to Black participants. This difference could be due to a variety of factors, including variations in the causes of cognitive impairment across racial groups, socioeconomic disparities, or differences in how the biomarker is processed in different populations. The researchers acknowledge that the smaller sample size of Black participants limits the ability to draw firm conclusions.

Among White participants with available genetic data, those who carried the APOE ε4 gene variant – a well-known genetic risk factor for Alzheimer’s disease – showed a stronger association between p-tau217 levels and both MCI and dementia. This suggests that the biomarker may be particularly useful for identifying individuals with a genetic predisposition to the disease who are at higher risk of cognitive decline.

Age also played a role. The association between p-tau217 and cognitive outcomes was stronger in women aged 70 years or older compared to those younger than 70. This finding aligns with the understanding that the risk of dementia increases with age.

What Does This Mean for Early Detection?

These findings underscore the potential of p-tau217 as a valuable tool for early dementia risk assessment. Currently, diagnosing Alzheimer’s disease often relies on identifying symptoms after significant brain damage has already occurred. A blood test that can detect early signs of the disease, even before symptoms appear, could allow for earlier intervention and potentially more effective treatment strategies. As reported by News-Medical.net, the study’s findings are a significant step towards that goal.

However, it’s crucial to remember that p-tau217 is not a definitive diagnostic test. It’s a risk marker, meaning it identifies individuals who are at higher risk of developing dementia, but it doesn’t guarantee that they will. The study’s findings are based on a specific population of postmenopausal women, and more research is needed to determine whether the results can be generalized to other populations, including men and younger adults.

Looking Ahead: Next Steps in Dementia Research

The research community is actively working to refine and validate the use of p-tau217 and other blood biomarkers for dementia risk assessment. Ongoing studies are investigating the biomarker’s performance in diverse populations and exploring its potential to predict the rate of cognitive decline. Researchers are also working to develop more accurate and reliable biomarker assays and to identify other biomarkers that can provide a more comprehensive picture of the underlying disease processes.

the goal is to develop a combination of biomarkers, along with clinical assessments and imaging studies, that can accurately identify individuals at risk of dementia and guide the development of personalized prevention and treatment strategies. The Women’s Health Initiative Memory Study and other ongoing research efforts are paving the way for a future where early detection and intervention can significantly improve the lives of those affected by Alzheimer’s disease and related dementias. The Science Media Centre provides expert reaction to this study, highlighting the importance of continued research in this area.